369
Views
2
CrossRef citations to date
0
Altmetric
Review

Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges

ORCID Icon, &
Pages 409-422 | Published online: 25 May 2020

References

  • Lanktree MB, Haghighi A, Guiard E, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol. 2018;29(10):2593–2600. doi:10.1681/ASN.2018050493
  • Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356–1363. doi:10.1093/ndt/gfw240
  • Spithoven EM, Kramer A, Meijer E, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival–an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014;29(Suppl 4):iv15–iv25. doi:10.1093/ndt/gfu017
  • Fernando MR, Dent H, McDonald SP, Rangan GK. Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014). Popul Health Metr. 2017;15(1):7. doi:10.1186/s12963-017-0123-7
  • Cornec-le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol. 2018;29(1):13–23. doi:10.1681/ASN.2017050483
  • Cornec-le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006–1013. doi:10.1681/ASN.2012070650
  • Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792–810. doi:10.1053/j.ajkd.2015.07.037
  • Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–735. doi:10.1053/j.ajkd.2014.01.416
  • Johnson DW, Atai E, Chan M, et al. KHA-CARI guideline: early chronic kidney disease: detection, prevention and management. Nephrology (Carlton). 2013;18(5):340–350. doi:10.1111/nep.12052
  • Johnson DW, Jones GR, Mathew TH, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012;197(4):224–225. doi:10.5694/mja11.11468
  • Jesudason S, Grace BS, McDonald SP. Pregnancy outcomes according to dialysis commencing before or after conception in women with ESRD. Clin J Am Soc Nephrol. 2014;9(1):143–149. doi:10.2215/CJN.03560413
  • Wyld ML, Clayton PA, Kennedy SE, Alexander SI, Chadban SJ. Pregnancy outcomes for kidney transplant recipients with transplantation as a child. JAMA Pediatr. 2015;169(2):e143626. doi:10.1001/jamapediatrics.2014.3626
  • Fitzpatrick A, Mohammadi F, Jesudason S. Managing pregnancy in chronic kidney disease: improving outcomes for mother and baby. Int J Womens Health. 2016;8:273–285. doi:10.2147/IJWH.S76819
  • Vora N, Perrone R, Bianchi DW. Reproductive issues for adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2008;51(2):307–318. doi:10.1053/j.ajkd.2007.09.010
  • Chapman AB, Johnson AM, Gabow PA. Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5(5):1178–1185.
  • Milutinovic J, Fialkow PJ, Agodoa LY, Phillips LA, Bryant JI. Fertility and pregnancy complications in women with autosomal dominant polycystic kidney disease. Obstet Gynecol. 1983;61(5):566–570.
  • Kidney Health Australia. Melbourne. Chronic Kidney Disease (CKD) management in general practice (3rd Edition); 2015. Available from https://kidney.org.au/health-professionals/prevent/chronic-kidney-disease-management-handbook. Accessed January 3, 2020..
  • Rangan GK, Alexander SI, Campbell KL, et al. KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology (Carlton). 2016;21(8):705–716. doi:10.1111/nep.12658
  • Campbell KL, Rangan GK, Lopez-Vargas P, Tong A. KHA-CARI autosomal dominant polycystic kidney disease guideline: diet and lifestyle management. Semin Nephrol. 2015;35(6):572–581. (). doi:10.1016/j.semnephrol.2015.10.008
  • Mallett A, Lee VW, Mai J, Lopez-Vargas P, Rangan GK. KHA-CARI autosomal dominant polycystic kidney disease guideline: pharmacological management. Semin Nephrol. 2015;35(6):582–589.. doi:10.1016/j.semnephrol.2015.10.009
  • Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25(1):18–32. doi:10.1681/ASN.2013040398
  • Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. doi:10.1056/NEJMoa1205511
  • Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33(3):477–489. doi:10.1093/ndt/gfx043
  • Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930–1942. doi:10.1056/NEJMoa1710030
  • Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122–2130. doi:10.1056/NEJMoa054341
  • Furukawa M, Umehara K, Kashiyama E. Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S83–S89. doi:10.1007/s10557-011-6357-x
  • Odutayo A, Hladunewich M. Obstetric nephrology: renal hemodynamic and metabolic physiology in normal pregnancy. Clin J Am Soc Nephrol. 2012;7(12):2073–2080. doi:10.2215/CJN.00470112
  • Munkhaugen J, Lydersen S, Romundstad PR, Wideroe TE, Vikse BE, Hallan S. Kidney function and future risk for adverse pregnancy outcomes: a population-based study from HUNT II, Norway. Nephrol Dial Transplant. 2009;24(12):3744–3750. doi:10.1093/ndt/gfp320
  • Fitzpatrick A, Venugopal K, Scheil W, McDonald SP, Jesudason S. The spectrum of adverse pregnancy outcomes based on kidney disease diagnoses: a 20-year population study. Am J Nephrol. 2019;49(5):400–409. doi:10.1159/000499965
  • Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med. 1996;335(4):226–232. doi:10.1056/NEJM199607253350402
  • Hladunewich MA, Melamed N, Bramham K. Pregnancy across the spectrum of chronic kidney disease. Kidney Int. 2016;89(5):995–1007. doi:10.1016/j.kint.2015.12.050
  • Wiles KS, Nelson-Piercy C, Bramham K. Reproductive health and pregnancy in women with chronic kidney disease. Nat Rev Nephrol. 2018;14(3):165–184. doi:10.1038/nrneph.2017.187
  • Piccoli GB, Cabiddu G, Attini R, et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol. 2015;26(8):2011–2022. doi:10.1681/ASN.2014050459
  • Piccoli GB, Cabiddu G, Castellino S, et al. A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian Study Group on  Kidney and Pregnancy. J Nephrol. 2017;30(3):307–317. doi:10.1007/s40620-017-0390-1
  • Zhang JJ, Ma XX, Hao L, Liu LJ, Lv JC, Zhang H. A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol. 2015;10(11):1964–1978. doi:10.2215/CJN.09250914
  • Wu M, Wang D, Zand L, et al. Pregnancy outcomes in autosomal dominant polycystic kidney disease: a case-control study. J Matern Fetal Neonatal Med. 2016;29(5):807–812. doi:10.3109/14767058.2015.1019458
  • Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med. 2015;372(2):124–133. doi:10.1056/NEJMoa1408932
  • Ibrahim HN, Akkina SK, Leister E, et al. Pregnancy outcomes after kidney donation. Am J Transplant. 2009;9(4):825–834.
  • Reisaeter AV, Roislien J, Henriksen T, Irgens LM, Hartmann A. Pregnancy and birth after kidney donation: the Norwegian experience. Am J Transplant. 2009;9(4):820–824.
  • Piccoli GB, Fassio F, Attini R, et al. Pregnancy in CKD: whom should we follow and why? Nephrol Dial Transplant. 2012;27(Suppl 3):iii111–iii118. doi:10.1093/ndt/gfs302
  • Haseler E, Melhem N, Sinha MD. Renal disease in pregnancy: fetal, neonatal and long-term outcomes. Best Pract Res Clin Obstet Gynaecol. 2019;57:60–76. doi:10.1016/j.bpobgyn.2019.01.018
  • Piccoli GB, Arduino S, Attini R, et al. Multiple pregnancies in CKD patients: an explosive mix. Clin J Am Soc Nephrol. 2013;8(1):41–50. doi:10.2215/CJN.02550312
  • Tong A, Brown MA, Winkelmayer WC, Craig JC, Jesudason S. Perspectives on pregnancy in women with CKD: a semistructured interview study. Am J Kidney Dis. 2015;66(6):951–961. doi:10.1053/j.ajkd.2015.08.023
  • Jesudason S, Tong A. The patient experience of kidney disease and pregnancy. Best Pract Res Clin Obstet Gynaecol. 2019;57:77–88. doi:10.1016/j.bpobgyn.2018.12.003
  • Tchan M, Savige J, Patel C, et al. KHA-CARI autosomal dominant polycystic kidney disease guideline: genetic testing for diagnosis. Semin Nephrol. 2015;35(6):545–549. doi:10.1016/j.semnephrol.2015.10.007
  • Patel C, Tchan M, Savige J, et al. KHA-CARI autosomal dominant polycystic kidney disease guideline: genetics and genetic counseling. Semin Nephrol. 2015;35(6):550–556. doi:10.1016/j.semnephrol.2015.10.003
  • Sujansky E, Kreutzer SB, Johnson AM, Lezotte DC, Schrier RW, Gabow PA. Attitudes of at-risk and affected individuals regarding presymptomatic testing for autosomal dominant polycystic kidney disease. Am J Med Genet. 1990;35(4):510–515. doi:10.1002/(ISSN)1096-8628
  • Swift O, Vilar E, Rahman B, Side L, Gale DP. Attitudes in patients with autosomal dominant polycystic kidney disease toward prenatal diagnosis and preimplantation genetic diagnosis. Genet Test Mol Biomarkers. 2016;20(12):741–746. doi:10.1089/gtmb.2016.0050
  • Sullivan-Pyke CS, Senapati S, Mainigi MA, Barnhart KT. In Vitro fertilization and adverse obstetric and perinatal outcomes. Semin Perinatol. 2017;41(6):345–353. doi:10.1053/j.semperi.2017.07.001
  • Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019;20(1):401. doi:10.1186/s12882-019-1560-2
  • Society of Obstetric Medicine Australia and New Zealand. SOMANZ guidelines for the management of hypertensive disorders of pregnancy; 2015. Available from https://www.somanz.org/guidelines.asp. Accessed January 3, 2020.
  • Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am J Obstet Gynecol. 1990;163(2):460–465. doi:10.1016/0002-9378(90)91176-D
  • Webster K, Fishburn S, Maresh M, Findlay SC, Chappell LC, Guideline C. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019;366:l5119. doi:10.1136/bmj.l5119
  • Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2014;160(10):695–703. doi:10.7326/M13-2844
  • Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622. doi:10.1056/NEJMoa1704559
  • Cabiddu G, Castellino S, Gernone G, et al. A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy. J Nephrol. 2016;29(3):277–303.
  • von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can. 2002;24(12):941–945. doi:10.1016/S1701-2163(16)30592-8
  • von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355(9198):87–92. doi:10.1016/S0140-6736(98)08049-0
  • Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255–2266. doi:10.1056/NEJMoa1402685
  • Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–417. doi:10.1056/NEJMoa1404595
  • Magee LA, von Dadelszen P, Singer J, et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study): is severe hypertension just an elevated blood pressure? Hypertension. 2016;68(5):1153–1159. doi:10.1161/HYPERTENSIONAHA.116.07862
  • Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10:CD002252.
  • NICE. Hypertension in pregnancy: diagnosis and management. Available from https://www.nice.org.uk/guidance/ng133. Accessed January 3, 2020..
  • Butalia S, Audibert F, Cote AM, et al. Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy. Can J Cardiol. 2018;34(5):526–531. doi:10.1016/j.cjca.2018.02.021
  • Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83(1):177–181. doi:10.1038/ki.2012.348
  • Bramham K, Seed PT, Lightstone L, et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int. 2016;89(4):874–885. doi:10.1016/j.kint.2015.10.012
  • Mandal D, Saha MM, Pal DK. Urological disorders and pregnancy: an overall experience. Urol Ann. 2017;9(1):32–36. doi:10.4103/0974-7796.198901
  • The Renal Association. United kingdom. clinical practice guideline pregnancy and renal disease; 2018. Available from https://renal.org/wp-content/uploads/2019/09/FINAL-Pregnancy-Guideline-September-2019.pdf. Accessed January 3, 2020..
  • Sallee M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(7):1183–1189. doi:10.2215/CJN.01870309
  • Lantinga MA, Casteleijn NF, Geudens A, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant. 2017;32(1):144–150. doi:10.1093/ndt/gfv452
  • Lantinga MA, Drenth JP, Gevers TJ. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2015;30(5):744–751. doi:10.1093/ndt/gfu227
  • Hamanoue S, Suwabe T, Ubara Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts. BMC Nephrol. 2018;19(1):272. doi:10.1186/s12882-018-1067-2
  • Kistler AD, Poster D, Wuthrich RP, Serra AL. Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney Int. 2009;76(12):1297. doi:10.1038/ki.2009.309
  • Ma TL, Neild GH. Parapelvic cyst misdiagnosed as hydronephrosis. Clin Kidney J. 2013;6(2):238–239. doi:10.1093/ckj/sfs189
  • Savige J, Tunnicliffe DJ, Rangan GK. KHA-CARI autosomal dominant kidney disease guideline: management of chronic pain. Semin Nephrol. 2015;35(6):607–611. (). doi:10.1016/j.semnephrol.2015.10.013
  • Australian Medicines Handbook. Australia. Available from https://amhonline.amh.net.au. Accessed March 20, 2020. Updated July 2019. Accessed December 30, 2019.
  • Lee VW, Dexter MA, Mai J, Vladica P, Lopez-Vargas P, Rangan GK. KHA-CARI autosomal dominant polycystic kidney disease guideline: management of intracranial aneurysms. Semin Nephrol. 2015;35(6):612–617. (). doi:10.1016/j.semnephrol.2015.10.014
  • Ars E, Bernis C, Fraga G, et al. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(Suppl 4):iv95–iv105. doi:10.1093/ndt/gfu186
  • Kim YW, Neal D, Hoh BL. Cerebral aneurysms in pregnancy and delivery: pregnancy and delivery do not increase the risk of aneurysm rupture. Neurosurgery. 2013;72(2):143–149. (). doi:10.1227/NEU.0b013e3182796af9
  • Tiel Groenestege AT, Rinkel GJ, van der Bom JG, Algra A, Klijn CJ. The risk of aneurysmal subarachnoid hemorrhage during pregnancy, delivery, and the puerperium in the Utrecht population: case-crossover study and standardized incidence ratio estimation. Stroke. 2009;40(4):1148–1151. doi:10.1161/STROKEAHA.108.539700
  • D’Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? Nephrol Dial Transplant. 2016;31(6):857–859. doi:10.1093/ndt/gfv417
  • Bae K, Park B, Sun H, et al. Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013;8(7):1089–1097. doi:10.2215/CJN.10561012
  • Chauveau D, Fakhouri F, Grunfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol. 2000;11(9):1767–1775.
  • van Aerts RMM, Bernts LHP, Gevers TJG, et al. Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients. Clin Pharmacol Ther. 2019;106(6):1338–1345. doi:10.1002/cpt.v106.6
  • Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology. 1997;26(5):1282–1286. doi:10.1002/hep.510260528
  • The Faculty of Sexual and Reproductive Healthcare. United kingdom. FSRH guideline contraception after pregnancy; 2017. Available from: https://www.fsrh.org/standards-and-guidance/documents/contraception-after-pregnancy-guideline-january-2017/. Accessed January 3, 2020.
  • Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2018;125(13):1642–1654. doi:10.1111/1471-0528.15394
  • Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41(5):1311–1319. doi:10.1038/ki.1992.195
  • Luyckx VA, Bertram JF, Brenner BM, et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet. 2013;382(9888):273–283. doi:10.1016/S0140-6736(13)60311-6
  • The Renal Association. United Kingdom. clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD). 2018. Available from https://renal.org/guidelines/. Accessed January 3, 2020.
  • Zachariah SK, Fenn M, Jacob K, Arthungal SA, Zachariah SA. Management of acute abdomen in pregnancy: current perspectives. Int J Womens Health. 2019;11:119–134. doi:10.2147/IJWH.S151501